Re­vance los­es at­tempt to dis­miss Botox trade se­crets law­suit

A Ten­nessee fed­er­al judge on Wednes­day de­clined to dis­miss a trade se­crets law­suit against Re­vance Ther­a­peu­tics, which launched a Botox ri­val in 2022 and is cur­rent­ly work­ing on a biosim­i­lar.

Ab­b­Vie’s Al­ler­gan unit filed suit against Re­vance last April, ac­cus­ing the com­pa­ny of poach­ing Al­ler­gan em­ploy­ees with ac­cess to trade se­crets for its Botox and Ju­vé­derm prod­ucts. Ab­b­Vie claimed it would be “very chal­leng­ing (if not im­pos­si­ble)” to pro­duce a Botox biosim­i­lar with­out ac­cess to “high­ly con­fi­den­tial” in­for­ma­tion, in­clud­ing the Botox ref­er­ence stan­dard and its strate­gies for de­ter­min­ing po­ten­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER